转移性食管癌患者接受积极原发肿瘤放疗可改善总生存
基于美国国家癌症数据库2004至2012年新诊断转移性食管癌患者的观察性队列研究,最终纳入12683例。与单纯化疗相比,化疗联合根治剂量放疗(≥5040 cGy)与总生存改善相关(中位总生存8.3个月对11.3个月,HR=0.72,95%CI 0.70-0.74,p≤0.001),而化疗联合姑息剂量放疗(<5040 cGy)与稍差结局相关(中位总生存8.3个月对7.5个月,HR=1.10,95%CI 1.07-1.13,p≤0.001)。
要点
- 化疗联合根治剂量放疗(≥5040 cGy)较单纯化疗与总生存改善相关,中位总生存8.3个月对11.3个月,HR=0.72(95%CI 0.70-0.74,p≤0.001)。
- 化疗联合姑息剂量放疗(<5040 cGy)较单纯化疗与稍差结局相关,中位总生存8.3个月对7.5个月,HR=1.10(95%CI 1.07-1.13,p≤0.001)。
- 作者认为局部控制可能对预后重要,支持将原发肿瘤定向放疗纳入未来临床试验以完善转移性食管癌的个体化治疗。
核心结论
- 根治剂量而非传统姑息剂量的原发肿瘤定向放疗与转移性食管癌总生存改善相关,提示局部控制可能对预后重要。
- 作者认为这些发现支持将原发肿瘤定向放疗纳入未来临床试验,以完善转移性食管癌患者的个体化治疗。
研究设计与样本
- 观察性队列研究,使用美国国家癌症数据库评估2004年至2012年新诊断的转移性食管癌患者。
- 采用倾向性评分逆概率治疗加权后的Cox比例风险模型比较总生存,并通过敏感性分析评估潜在未测量混杂。
主要发现
- 最终队列共12683例:57%接受单纯化疗,24%接受化疗联合姑息剂量放疗,19%接受化疗联合根治剂量放疗。
- 与单纯化疗相比,化疗联合根治剂量放疗与生存改善相关,中位总生存8.3个月对11.3个月(HR=0.72,95%CI 0.70-0.74,p≤0.001)。
- 与单纯化疗相比,化疗联合姑息剂量放疗与稍差结局相关,中位总生存8.3个月对7.5个月(HR=1.10,95%CI 1.07-1.13,p≤0.001)。
- 敏感性分析显示上述发现在潜在未测量混杂下稳健,界标分析在生存12个月及以上的患者中证实了这些发现。
关键数值与推荐
- 姑息剂量放疗定义为<5040 cGy。
- 根治剂量放疗定义为≥5040 cGy。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The aim of this study was to characterize utilization and survival outcomes associated with primary tumor-directed radiotherapy (PTDRT) in patients with newly diagnosed metastatic esophageal cancer. METHODS: We conducted an observational cohort study using the National Cancer Data Base to evaluate patients with newly diagnosed metastatic esophageal cancer between 2004 and 2012. Overall survival outcomes after treatment with chemotherapy plus conventional palliative dose radiotherapy (<5040 cGy), chemotherapy plus definitive dose radiotherapy (≥5040 cGy), or chemotherapy alone were compared by using Cox proportional hazards models with inverse probability of treatment weighting using the propensity score. Potential unmeasured confounding was assessed through sensitivity analyses. RESULTS: The final cohort consisted of 12,683 patients: 57% were treated with chemotherapy alone, 24% were treated with chemotherapy plus palliative dose radiotherapy, and 19% were treated with chemotherapy plus definitive dose radiotherapy. Compared with chemotherapy alone, chemotherapy plus definitive dose radiotherapy was associated with improved survival (median overall survival of 8.3 versus 11.3 months [hazard ratio = 0.72, 95% confidence interval: 0.70-0.74, p ≤ 0.001]), whereas chemotherapy plus palliative dose radiotherapy was associated with slightly inferior outcomes (median overall survival of 8.3 months versus 7.5 months (hazard ratio = 1.10, 95% confidence interval 1.07-1.13, p ≤ 0.001). These findings were robust to potential unmeasured confounding in sensitivity analyses. Additionally, landmark analyses confirmed these findings in patients surviving 12 months or longer. CONCLUSIONS: Definitive dose, but not conventional palliative dose, PTDRT is associated with improved overall survival in metastatic esophageal cancer, suggesting that local control may be important to prognosis. These findings support integrating PTDRT into future clinical trials aimed at refining personalized treatment for patients with metastatic esophageal cancer.
引用
- Guttmann DM, Mitra N, Bekelman J, et al. Improved Overall Survival with Aggressive Primary Tumor Radiotherapy for Patients with Metastatic Esophageal Cancer. J Thorac Oncol. 2017. PMID: 28461255. doi:10.1016/j.jtho.2017.03.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。